ClinicalTrials.gg
CompletedNCT01526746Updated Feb 17, 2014

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

A Phase 1 interventional study of Tasimelteon and Tasimelteon in Renal Impairment, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-17.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
216th of 468
32 · median 32
Started
2012
with 22 others
Phase 1
232 of 553
14 open now
Registered
211th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 216th largest by enrollment of the 468 interventional ones that give a count, is one of 23 that started in 2012, is one of 232 in phase 1, and was the 211th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.

03

Conditions studied

  • Renal Impairment

Keywords

  • End stage renal disease
  • ESRD
  • kidney disease
  • renal impairment
  • renal
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Groups 1-3

  1. Ability and acceptance to provide written ;
  2. Men or women between 18 - 79 years, inclusive;
  3. Subjects with (BMI) of >18 and \<40 kg/m2 (BMI = weight (kg)/ [height (m)]2);
  4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is , without menses for 6 months before screening), or females of using an acceptable method of for a period of 35 days before the first dosing and have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.
  5. Willing and able to comply with study requirements and restrictions;

Groups 1- 2 (renal impairment)

  1. Subjects with renal impairment defined as

    1. Group 1: Stage 5 End Stage Renal Disease (ESRD) ( \< 15 mL/min/m2) requiring regularly scheduled dialysis and have been on a stable dialysis regimen for at least three months at baseline; OR
    2. Group 2: Stage 4 severe renal impairment (eGFR ≤ 29 mL/min/m2) but not requiring dialysis as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3)
  2. Otherwise considered healthy in general as determined by past medical history, physical examination, vital signs, , and laboratory tests at screening;
  3. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below.

    1. Body temperature between 35.0-37.5 °C;
    2. Systolic blood pressure between 100-180 mmHg;
    3. Diastolic blood pressure between 60-115 mmHg;
    4. Pulse rate between 40-100 bpm.

Group 3 (healthy matched controls)

  1. Subjects in Group 3 must match in gender, smoking status, age (±10 years), and body mass index [normal BMIs (18.00-24.99), overweight BMIs (25.00-30.99) and obese BMIs (31.00-40.00)] to Group 1 and/or 2;
  2. Subjects must have normal renal function defined as eGFR ≥ 80 mL/min/m2 as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3 );
  3. Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis;
  4. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    1. Body temperature between 35.0 - 37.5 °C;
    2. Systolic blood pressure between 90 - 150 mmHg;
    3. Diastolic blood pressure between 50 - 95 mmHg;
    4. Pulse rate between 40 - 90 bpm.

Exclusion criteria

Exclusion Criteria:

Groups 1-3

  1. Smokers (use of tobacco products in the previous 3 months) unable or unwilling to limit consumption to 10 cigarettes per day or less while checked into the inpatient facility.

    a. Note: Smoking will be a match criteria and the site should attempt to enroll an equal number of smokers and non-smokers into each group.

  2. Exposure to any investigation drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of dosing;
  3. Donation or loss of 400 mL or more of blood within two months prior to dosing;
  4. Significant illness within the two weeks prior to dosing;
  5. Answer 'yes' to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or answer "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "Suicidal Behavior" portion of the Columbia Suicide Severity Rating Scale (C-SSRS); and the ideation or behavior occurred within the past 6 months;
  6. Functioning renal transplant;
  7. History within the past 2 years of acute or chronic bronchospastic disease, including asthma and , treated or not treated;
  8. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 day preceding the Screening visit;
  9. Participation in a previous BMS-214778/VEC-162 trial;
  10. History of drug or alcohol abuse as defined in , Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during the screening and baseline visits. A positive drug screen in Groups 1 and 2 is acceptable if there is documentation that subjects have been prescribed the corresponding medication;
  11. History of immunocompromise, including a positive (ELISA and Western blot) test result;
  12. A positive surface antigen (HBsAg) test result;
  13. Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug. The Investigator should be guided by evidence of any of the following:

    1. History of clinically significant inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
    2. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
    3. History of pancreatic injury or pancreatitis;
    4. History or presence of liver disease or liver injury as indicated by lab values such as , SGPT, GGT, alkaline phosphatase, or serum 1.5 times greater than the ;
  14. Clinically significant abnormalities or vital sign abnormalities at screening or a history of unstable, severe, or clinically significant cardiovascular disease (e.g., myocardial infarction within previous 6 months, unstable angina, cardiac failure, second/third degree atrioventricular block);
  15. Subjects taking any unapproved prescription or over-the-counter medications; all concomitant medications must be discussed with and approved by the sponsor prior to enrollment;
  16. A known to tasimelteon or drugs similar to tasimelteon including melatonin;
  17. Pregnant or lactating females;
  18. Inability to swallow the study medication whole;
  19. Any other sound medical reason as determined by the clinical Investigator.

Groups 1 - 2 (renal impairment)

  1. Subjects with clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG, or laboratory evaluation;
  2. Evidence of progressive renal disease within 4 weeks prior to screening;
  3. Acute renal failure or nephrotic syndrome;
  4. Current hematuria of urologic origin;
  5. Any significant change in chronic treatment medication as determined by the clinical Investigator.

Group 3 (healthy matched controls)

  1. Use of unapproved prescription medication within 1 month of dosing and OTC medication within 14 days prior to dosing;
  2. History or presence of impaired renal function as indicated by abnormal (>ULN) creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).
  3. A positive test result.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    End Stage Renal Disease, dialysis

    eGFR \<15 ml/min/1.73m\^2

    Drug: Tasimelteon

  • Experimental
    Severe renal impairment

    eGFR \< 29 ml/min/1.73m\^2

    Drug: Tasimelteon

  • Experimental
    Healthy controls

    eGFR \> 80 mL/min/1.73m\^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status

    Drug: Tasimelteon

Interventions

06

What researchers measure

Primary outcomes

  1. Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)

    Time frame: Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose

Secondary outcomes

  1. Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M3, M9, M11, M12, M13, and M14

    Time frame: Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose

  2. The percentage of tasimelteon and its metabolites that are removed by hemodialysis (AUC)

    paired arterial and venous samples

    Time frame: 4, 6, 8 hours after dosing

  3. The ratio of plasma protein bound versus unbound fractions of tasimelteon and metabolites M9, M11, M12, M13, and M14

    Time frame: 0.5 and 3 hours post dose

  4. Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signs

    Time frame: 36 hours

  5. The Columbia-Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation.

    Time frame: once per day at Screening (approximately day -7), Day -1 (baseline), Day 2 (end of study)

07

Study locations

3 sites
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • DaVita Clinical Research
    Minneapolis, Minnesota, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2012
First posted
Feb 6, 2012
Start
Feb 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Feb 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01526746
Responsible party
Sponsor
First posted
Feb 6, 2012
Start date
Feb 2012
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Feb 17, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion